Note 11 – Subsequent Events

Issuance of True-Up Shares

On July 1, 2026, the Company issued 463,636 shares of Common Stock to the investors under the Securities Purchase Agreements entered into on May 30, 2025 and June 1, 2025 and closed on June 30, 2025, in settlement of the True-Up obligation that became fixed during the three months ended June 30, 2026 (see Note 7).

Termination of CoFame Management Consulting Agreement

On June 29, 2026, the Company and CoFame Management mutually agreed to terminate the Consulting Agreement (see Note 5), effective July 1, 2026. All accrued fees and expenses through June 30, 2026 are payable by August 31, 2026. In connection with the termination, 520,858 unvested shares underlying the Advisory Consulting Service Award were forfeited effective July 1, 2026, while 479,142 vested shares remain exercisable through October 1, 2026.

Office Sublease Renewal

Effective July 1, 2026, the Company entered into a successor short-term office sublease with Eureka for the period from July 1, 2026 through December 31, 2026, at a monthly fee of $2,000.

Milestones under Statement of Work #001

In July 2026, one additional patient was dosed in the STARLIGHT-1 clinical trial. The Company accrued an additional $1.375 million for this milestone under the SOW.

Except as described above, the Company did not identify any other subsequent events that would require recognition or disclosure in these unaudited condensed consolidated financial statements.